Omni Partners’s Pacific Biosciences PACB Stock Holding History

Omni Partners’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-505,684	Closed	-$3.66M	–	36
2019 Q1	$3.66M	Buy	505,684 +18,377	+4%	+$133K	0.4%	24
2018 Q4	$3.61M	Buy	+487,307	New	+$3.09M	0.78%	20

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

WIC

Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return

Omni Partners's PACB Position: Q2 2019 in Review

Omni Partners sold out of Pacific Biosciences (PACB) in Q2 2019, closing a stake of 505,684 shares — an estimated $3.66M sold.

Omni Partners first reported a position in PACB in Q4 2018 and held it in 2 quarters. The position peaked at $3.66M in Q1 2019. 150 funds tracked by Wall St. Rank hold PACB as of Q2 2019.

Omni Partners reported no remaining Pacific Biosciences position as of Q2 2019 after selling out during the quarter.
Omni Partners sold 505,684 Pacific Biosciences shares in Q2 2019, an estimated $3.66M.
Omni Partners first reported a position in Pacific Biosciences in Q4 2018 and held it in 2 quarters.
Omni Partners's Pacific Biosciences position peaked at $3.66M in Q1 2019.
150 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2019.

Based on Omni Partners's 13F filing for Q2 2019, filed 14 Aug 2019.